Validation of the UCLA Scleroderma Clinical Trial Gastrointestinal Tract Instrument Version 2.0 for Systemic Sclerosis.
Posted 13 July 2011 - 11:45 PM
Our study confirms that the UCLA SCTC GITI version 2.0 will be a useful tool for assessing the role of GI involvement in SSc, even in a population with substantially different characteristics than the subjects originally tested. Baron M. (PubMed) J Rheumatol. 2011 Jul 1. (Also see: GI Involvement)
This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
ISN Assistant Webmaster
ISN Sclero Forums Manager
ISN News Manager
ISN Hotline Support Specialist
ISN Chat Host
International Scleroderma Network (ISN)